Citations

Mayo Clinic

Showing 10 of 108523 citations.

RhoC maintains vascular homeostasis by regulating VEGF-induced signaling in endothelial cells
Hoeppner, Luke H. , Wang, Ying , Dutta, Shamit K., Gong, Xun , Bedell, Victoria M. , Suresh, Sandip , Chun, Chang Zoon, Ramchandran, Ramani , Ekker, Stephen C. , Bhattacharya, Resham , Dutta, Shamit, Sinha, Sutapa , Mukhopadhyay, Debabrata , Ekker, Stephen C , Gong, Xun , Wang, Ying

Journal of Cell Science | July 2, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1242/jcs.167601 | PMID 26136364 Get It

Vasculogenesis and angiogenesis are controlled by vascular permeability factor/vascular endothelial growth factor A (VEGF). Dysregulation of these physiological processes contributes to the pathologies of heart disease, cancer and stroke. Rho GTPase proteins play an integral role in VEGF-mediated formation and maintenance of blood vessels. The regulatory functions of RhoA and RhoB in vasculogenesis and angiogenesis are well defined, whereas the purpose of RhoC remains poorly understood. Here, we describe how RhoC promotes vascular homeostasis by modulating endothelial cell migration, proliferation, and permeability. RhoC stimulates proliferation of human umbilical vein endothelial cells (HUVEC) by stabilizing nuclear β-catenin, which promotes transcription of cyclin D1 and subsequently drives cell cycle progression. RhoC negatively regulates endothelial cell migration through MAPK and downstream MLC-2 signaling and decreases vascular permeability through downregulation of the phospholipase Cγ (PLCγ)/Ca2+/eNOS cascade in HUVEC. Using a VEGF-inducible zebrafish (Danio rerio) model, we observed significantly less vascular permeability in RhoC morpholino (MO)-injected zebrafish than control MO-injected zebrafish. Taken together, our findings suggest RhoC is a key regulator of vascular homeostasis in endothelial cells.
Genitourinary Procedures as Risk Factors for Prosthetic Hip or Knee Infection: A Hospital-Based Prospective Case-Control Study
Osmon, Douglas R. , Hanssen, Arlen D. , Lightner, Deborah J., Wilson, Walter R., Steckelberg, James M., Harmsen, William S. , Mandrekar, Jay , Berbari, Elie F. , Mandrekar, Jay N., Gupta, Arjun , Baddour, Larry M.

Open Forum Infectious Diseases | July 2, 2015 | Volume: 2 | Issue: 3 | Pages: No page available

10.1093/ofid/ofv097 | PMID 26258154 Get It

Abstract Background. The purpose of this study was to determine the risk of prosthetic joint infection (PJI) as a complication of routine genitourinary (GU) procedures in patients with total hip arthroplasty (THA) or total knee arthroplasty (TKA) and to study the impact of antibiotic prophylaxis administered prior to these procedures. Methods. We conducted a prospective, single-center, case-control study between December 1, 2001 and May 31, 2006. Case patients were hospitalized with total hip or knee PJI. Control subjects underwent a THA or TKA and were hospitalized during the same period on the same orthopedic floor without a PJI. Data regarding demographic features and potential risk factors were collected. The outcome measure was the odds ratio (OR) of PJI after GU procedures performed within 2 years of admission. Results. A total of 339 case patients and 339 control subjects were enrolled in the study. Of these, 52 cases (15%) and 55 controls (16%) had undergone a GU procedure in the preceding 2 years. There was no increased risk of PJI for patients undergoing a GU procedure with or without antibiotic prophylaxis (adjusted OR [aOR] = 1.0, 95% confidence interval [CI] = 0.2–4.5, P = .95 and aOR = 1.0, 95% CI = 0.6–1.7, P = .99, respectively). Results were similar in a subset of patients with a joint age less than 6 months, less than 1 year, or greater than 1 year. Conclusions. Genitourinary procedures were not risk factors for subsequent PJI. The use of antibiotic prophylaxis before GU procedures did not decrease the risk of subsequent PJI in our study.
Exercise adaptations: A red herring?
Lanza, Ian R. , Lanza, Ian R

Science Translational Medicine | July 1, 2015 | Volume: 7 | Issue: 294 | Pages: No page available

10.1126/scitranslmed.aac8104 Get It

Patients with type 2 diabetes reap benefits from exercise even if they do not exhibit improved cardiorespiratory fitness.
Adapt or Perish
Sieck, Gary C. , Sieck, Gary

Physiology | July 1, 2015 | Volume: 30 | Issue: 4 | Pages: 258-259

10.1152/physiol.00023.2015 | PMID 26136539 Get It

Technology Use for Problem Solving in Adolescent Type 1 Diabetes
Hinshaw, Ling , Basu, Ananda

Diabetes Technology & Therapeutics | July 1, 2015 | Volume: 17 | Issue: 7 | Pages: 443-444

10.1089/dia.2015.0175 | PMID 26132765 Get It

Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa
Santiago, Tania M. González, Zavialov, Andrey V. , Saarela, Janna , Seppänen, Mikko , Reed, Ann M. , Abraham, Roshini S. , Gibson, Lawrence E. , Gonzalez Santiago, Tania M

JAMA Dermatology | July 1, 2015 | Volume: 151 | Issue: 11 | Pages: 1230

10.1001/jamadermatol.2015.1635 | PMID 26131734 Get It

Management of opioid-induced constipation for people in palliative care
Prichard, David O. , Bharucha, Adil E. , Bharucha, Adil

International Journal of Palliative Nursing | July 1, 2015 | Volume: 21 | Issue: 6 | Pages: 272-280

10.12968/ijpn.2015.21.6.272 | PMID 26126675 Get It

Constipation is common in the palliative population. Opioid medications, which are frequently prescribed to this cohort, represent a significant risk factor for this condition. Opioid-induced constipation may be of such severity that opioid doses are reduced or missed, and analgesia and quality of life are therefore reduced. However, underlying chronic constipation, local and systemic disease effects, and other medications may also precipitate constipation in this population. The assessment and treatment of constipation in a palliative individual should be undertaken in a fashion similar to that used in non-palliative patients. Initial management should include minimising exposure to predisposing factors and general measures such as encouraging hydration, fibre intake and mobility. Pharmacological treatment should commence with a stool softener and a stimulant laxative. Recently published literature demonstrates that newer laxatives, including lubiprostone (a chloride channel activator) and prucalopride (a 5-HT4 receptor agonist) can effectively treat opioid-induced constipation. For patients not responding to laxatives, opioid antagonists (non-specific or peripherally acting μ-opioid receptor antagonists) can be co-prescribed with laxatives. These agents have also proven efficacy in treating opioid-induced constipation. This review discusses the recent literature regarding the management of opioid-induced constipation and provides a rational approach to assessing and managing constipation in the palliative population.
Interprofessional education: First steps
Pawlina, Wojciech, Drake, Richard L.

Anatomical Sciences Education | July 1, 2015 | Volume: 8 | Issue: 4 | Pages: 289-290

10.1002/ase.1551 | PMID 26139224 Get It

Somatostatin analogues improve health‐related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo‐controlled trials
Neijenhuis, Myrte K., Nevens, Frank, Hogan, Marie C. , Torres, Vicente E. , Kievit, Wietske , Drenth, Joost P.H. , Gevers, Tom J.G. , Torres, Vicente E , Hogan, Marie C , Drenth, Joost P H

Alimentary Pharmacology & Therapeutics | July 1, 2015 | Volume: 42 | Issue: 5 | Pages: 591-598

10.1111/apt.13301 | PMID 26129925 Get It

SummaryBackgroundPolycystic liver disease is associated with impaired health‐related quality of life (HRQL). Somatostatin analogues reduce hepatomegaly in polycystic liver disease.AimTo determine whether somatostatin analogues improve HRQL and to identify factors associated with change in HRQL in polycystic liver disease.MethodsWe pooled data from two randomized, double‐blind, placebo‐controlled trials that evaluated HRQL using the Short‐Form 36 (SF‐36) in 96 polycystic liver disease patients treated 6‐12 months with somatostatin analogues or placebo. The SF‐36 contains a summarizing physical and mental component score and was administered at baseline and at the end of treatment. We used random effect models to delineate the effect of somatostatin analogues on HRQL. We determined the effect of demographics, height‐adjusted liver volume, change in liver volume, somatostatin analogue‐associated side effects with change in HRQL. In patients with autosomal dominant polycystic kidney disease, we estimated the effect of height‐adjusted kidney volume and change in kidney volume in relation to HRQL.ResultsPhysical component scores improved with somatostatin analogues, but remained unchanged with placebo (3.41 ± 1.29 vs. −0.71 ± 1.54, P = 0.044). Treatment had no impact on the mental component score. Large liver volume was independently associated with larger HRQL decline during follow up (−4.04 ± 2.02 points per logarithm liver volume, P = 0.049). In autosomal dominant polycystic kidney disease, patients with large liver and kidney volumes had larger decline in HRQL (5.36 ± 2.54 points per logarithm liver volume; P = 0.040 and −4.00 ± 1.88 per logarithm kidney volume; P = 0.039).ConclusionSomatostatin analogues improve HRQL in symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver disease is necessary to prevent further decline of HRQL in severe hepatomegaly.
Occult Temporal Bone Facial Nerve Involvement by Parotid Malignancies with Perineural Spread
Carlson, Matthew L. , Patel, Neil , Modest, Mara C., Moore, Eric J. , Janus, Jeffrey R. , Olsen, Kerry D.

Otolaryngology–Head and Neck Surgery | July 1, 2015 | Volume: 153 | Issue: 3 | Pages: 385-391

10.1177/0194599815591160 | PMID 26129739 Get It

ObjectiveTo characterize disease presentation and outcomes following surgical treatment of parotid malignancies with occult temporal bone facial nerve (FN) involvement.Study DesignCase series with chart review.SettingTertiary academic referral center.Subjects and MethodsThirty consecutive patients (mean age 58 years; 77% men) who underwent surgery for parotid malignancies with occult perineural involvement of the intratemporal FN were included. Primary outcome measures included margin status and recurrence.ResultsThe mean duration of clinical follow‐up was 49 months, and the most common presenting symptom was FN paresis (n = 23; 77%) followed by pain (n = 15; 50%). To obtain a proximal FN margin, 27 patients (90%) underwent mastoidectomy, and 3 patients (10%) had lateral temporal bone resection. The intratemporal FN margin was cleared in 26 patients (87%), most commonly in the mastoid segment (60%). Adjuvant therapy was given in 25 patients (83%). Ten patients (33%) experienced locoregional (4; 13%) and/or distant (8; 27%) recurrence at a median of 19 months (mean 26, 2–54 months) following surgery. Locoregional failure was significantly more common in cases with a positive intratemporal FN margin (66% vs 8%; P =. 045). Overall 1‐, 3‐, and 5‐year disease‐specific survival rates were 83%, 79%, and 72%, respectively.ConclusionsPerineural invasion of the intratemporal FN by parotid malignancy is uncommon. Normal preoperative FN function does not preclude histopathologic involvement. Temporal bone FN exploration should be considered when a positive margin is encountered at the stylomastoid foramen, as failure to do so is associated with an increased rate of locoregional recurrence.